Hengdi Pharmaceutical: Approval granted for the listing application of Erlotinib Hydrochloride chemical raw material drug

On February 3rd, Hengdi Pharmaceutical announced that the company recently received the "Chemical Drug Marketing Application Approval Notice" issued by the National Medical Products Administration for the approval of the listing of Erlotinib Hydrochloride. Erlotinib hydrochloride is a domestically developed EGFR tyrosine kinase inhibitor targeted drug, primarily used to treat locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the epidermal growth factor receptor gene. It can also be used for the treatment of advanced non-small cell lung cancer patients who have failed previous chemotherapy.